Valeant Scandal: The Pharmaceutical Enron

Key Takeaways

• Valeant grew by acquiring drugs and raising prices, not by research, until the model broke.
• A secret, captive pharmacy called Philidor inflated reported revenue and growth.
• The stock fell from near $262 in 2015 to about $11 by 2017, over 90 percent.
• The SEC fined the company $45 million; two executives were convicted of kickback fraud.

Background

Valeant Pharmaceuticals International was a Canadian specialty drugmaker that, under chief executive J. Michael Pearson, abandoned the industry's usual playbook. Instead of spending heavily on research to invent new medicines, Valeant bought existing drugs and companies, cut their research budgets, and raised the prices of the products it acquired. Wall Street rewarded the strategy, treating Valeant as a disciplined capital allocator rather than a traditional pharma company.

The acquisition machine ran fast. Valeant bought eye-care maker Bausch + Lomb in 2013 and gastrointestinal drugmaker Salix Pharmaceuticals in 2015, layering on debt to fund the deals. Each purchase brought drugs whose prices could be raised, and the resulting revenue made the roll-up look like organic growth. By August 2015, the stock closed at a record high around $262, valuing the company in the tens of billions of dollars (CNBC; contemporaneous reporting).

The strategy attracted high-profile backers. Bill Ackman's Pershing Square Capital Management took a large, concentrated stake and publicly vouched for management. For a time, Valeant was one of the most widely held and most admired names among hedge funds. The confidence of a respected activist investor became part of the bull case, and many holders treated his conviction as a substitute for their own diligence.

Beneath the headline growth, two pressures were building. The price increases were drawing political attention, and the "organic growth" the company advertised depended on a distribution arrangement that investors could not see.

What Happened

The acute phase of the Valeant scandal unfolded across 2015 and 2016, beginning with drug pricing and ending with a restatement and a leadership purge.

• February 2015: Valeant acquires the heart drugs Isuprel and Nitropress from Marathon Pharmaceuticals and raises their U.S. list prices by about 525 percent and 212 percent (U.S. House Oversight Committee, Aug. 14, 2015).
• April 1, 2015: Valeant acquires the diabetes drug Glumetza and later raises its price roughly 500 percent (SEC Order 33-10809).
• August 14, 2015: Representative Elijah Cummings and Senator Bernie Sanders open a congressional investigation into the Isuprel and Nitropress increases.
• August 2015: Valeant stock peaks at a record close near $262 (CNBC; contemporaneous reporting).
• October 21, 2015: Citron Research, run by short seller Andrew Left, publishes a report calling Valeant "the pharmaceutical Enron" and alleging it used a hidden pharmacy, Philidor, to book revenue. The stock falls as much as 39 percent intraday before closing down about 19 percent (CNBC; Citron Research).
• October 30, 2015: Valeant announces it is severing ties with Philidor, which will wind down.
• December 28, 2015: Pearson goes on indefinite medical leave after hospitalization for severe pneumonia; an executive committee runs the company (BioPharma Dive).
• March 21, 2016: Valeant says Pearson will step down once a successor is found; Bill Ackman joins the board.
• April 2016: Valeant restates its 2014 financial statements, reducing improperly recognized revenue (SEC Press Release 2020-169).
• May 2016: Joseph Papa replaces Pearson as chief executive.

The Citron report on October 21, 2015 was the turning point. By comparing Valeant to Enron and pointing to an undisclosed pharmacy, it reframed the company from a growth story into a possible fraud, and the market reaction was immediate and violent. Within days, Valeant cut ties with Philidor, and pharmacy benefit managers terminated their contracts with it.

Why It Happened

The Valeant scandal ran on two engines: aggressive price increases on acquired drugs, and a captive pharmacy that disguised where the resulting revenue came from.

Start with pricing. Valeant's growth depended on buying drugs and raising their prices far faster than any improvement in the product. After acquiring Isuprel and Nitropress from Marathon Pharmaceuticals in February 2015, it raised their U.S. list prices by about 525 percent and 212 percent, according to the congressional investigation opened by Cummings and Sanders. Valeant was the only seller of both heart drugs, so hospitals had little choice but to pay. The same pattern hit Glumetza, a diabetes drug Valeant acquired on April 1, 2015 and then repriced by roughly 500 percent.

The accounting problem grew directly out of that pricing. The SEC found that Valeant misattributed the revenue from the Glumetza price increase, spreading it across more than 100 unrelated products rather than booking it where it came from. That allocation mattered because, in its SEC filings and earnings presentations for the second and third quarters of 2015 and its year-end report, Valeant did not disclose how the single price increase had inflated its reported figures (SEC Order 33-10809). The trick made growth look broad-based when it was concentrated in one repriced drug.

The second engine was Philidor. This was a specialty mail-order pharmacy formed in early 2013 with Valeant's help. On paper it was independent, but Valeant had funded it, subsidized it, and held an option to buy it, and at least 90 percent of the drugs Philidor dispensed were Valeant-branded (DOJ, Oct. 30, 2018). Philidor existed to push Valeant's higher-priced drugs through insurance reimbursement, steering patients away from cheaper generics. Valeant recognized revenue on sales to and through this captive channel, then touted "double-digit same store organic growth" for five consecutive quarters without disclosing how much of it depended on Philidor or the risks tied to it (SEC Press Release 2020-169).

The structure is a textbook case of channel quality masking poor revenue quality. When sales flow through a controlled intermediary that the public cannot see, reported growth can be manufactured at the channel rather than earned in the market. Citron's October 2015 report argued that this amounted to using Philidor and related entities to create invoices and book revenue, the comparison that earned Valeant the "pharmaceutical Enron" label.

By the Numbers

• Stock peak: record close near $262 in August 2015. (CNBC; contemporaneous reporting)
• Isuprel and Nitropress increases: about 525 percent and 212 percent after the February 2015 Marathon purchase. (U.S. House Oversight Committee)
• Glumetza increase: roughly 500 percent on a drug acquired April 1, 2015. (SEC Order 33-10809)
• Misallocated revenue: Glumetza price-increase revenue spread across more than 100 unrelated products. (SEC Press Release 2020-169; SEC Order 33-10809)
• Organic-growth claim: double-digit "same store organic growth" touted for five consecutive quarters. (SEC Press Release 2020-169)
• Philidor concentration: at least 90 percent of drugs dispensed by Philidor were Valeant-branded. (DOJ, Oct. 30, 2018)
• Citron report impact: stock fell as much as 39 percent intraday on October 21, 2015, closing down about 19 percent. (CNBC; Citron Research)
• Option payment: Valeant paid $133 million for an option to buy Philidor, plus up to $100 million in milestone payments. (DOJ, Oct. 30, 2018)
• Kickback: the Philidor CEO routed $9.7 million to a Valeant executive through shell companies. (DOJ, Oct. 30, 2018)
• SEC penalty: $45 million paid by the company; about $985,000 in combined penalties and repayments from three executives. (SEC Press Release 2020-169)
• Stock trough: about $11 by March 2017, more than 90 percent below the 2015 peak. (CNBC)

Aftermath

The accounting case was resolved by civil settlement. On July 31, 2020, the SEC announced that Bausch Health, the renamed Valeant, agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures. The company and three former executives consented without admitting or denying the findings, which included violations of the antifraud provisions of Sections 17(a)(2) and 17(a)(3) of the Securities Act. Former CEO J. Michael Pearson agreed to a $250,000 civil penalty and to reimburse the company $450,000; former CFO Howard Schiller agreed to a $100,000 penalty and $110,000 in reimbursement; and former controller Tanya Carro agreed to a $75,000 penalty and to be suspended from practicing before the SEC as an accountant, with the ability to apply for reinstatement after one year (SEC Press Release 2020-169).

The criminal case targeted the Philidor relationship itself. Gary Tanner, the Valeant executive responsible for managing Philidor, and Andrew Davenport, Philidor's former CEO, were found guilty by a federal jury on May 22, 2018 of conspiracy to commit honest services wire fraud, honest services wire fraud, conspiracy to violate the Travel Act, and conspiracy to commit money laundering. Prosecutors showed that Davenport secretly routed $9.7 million to Tanner through shell companies while Tanner was supposed to be representing Valeant's interests, even using a fake "Brian Wilson" email account to hide the communications. On October 30, 2018, Senior U.S. District Judge Loretta Preska sentenced each man to 1 year and 1 day in prison, two years of supervised release, and ordered each to forfeit about $9.7 million (DOJ, Oct. 30, 2018).

The leadership and the company changed shape entirely. Pearson went on medical leave in December 2015, returned briefly, then agreed to step down in March 2016, with Joseph Papa taking over as chief executive in May 2016. The pricing increases drew sustained political fire; Pearson appeared before the U.S. Senate Special Committee on Aging in 2016 and called the increases a mistake. The stock kept falling, reaching about $11 in March 2017 when Bill Ackman's Pershing Square sold its remaining stake at a large loss, estimates of which range from roughly $2.8 billion on its year-end 2016 holdings to about $4 billion across the full position (CNBC; contemporaneous reporting). On May 8, 2018, the company announced it would rename itself Bausch Health Companies and change its ticker from VRX to BHC, a rebrand completed in July 2018 (PR Newswire).

Lessons for Investors

1. Price increases are not a growth strategy with a long life. Valeant's revenue came from raising prices on drugs it acquired, such as the roughly 525 percent and 212 percent jumps on Isuprel and Nitropress. When a business depends on repricing rather than volume or innovation, regulators, payers, and politicians eventually push back. Treat outsized pricing power on essential products as a risk to future revenue, not a permanent advantage.

2. Trace revenue to its real source. The SEC found Valeant spread the revenue from one Glumetza price increase across more than 100 unrelated products, making concentrated gains look broad-based. When you cannot tell which products or customers actually drove a quarter's growth, assume the disclosure is hiding concentration, and discount the "organic" growth the company advertises.

3. Captive channels poison revenue quality. Philidor was funded and controlled by Valeant but presented as independent, and at least 90 percent of what it dispensed was Valeant's own drugs. Sales booked through an undisclosed, controlled intermediary are only as trustworthy as the disclosure of that channel. A material distribution arrangement belongs in the filings, not in a short seller's report.

4. A famous backer is not your due diligence. Many investors held Valeant partly because Bill Ackman publicly vouched for it, and Pershing Square ultimately lost billions. A large, concentrated position by a skilled investor signals conviction, not verified accounting. You still have to read the filings, reconcile non-GAAP figures to GAAP, and test the revenue yourself.

5. Listen to credible skeptics before the restatement, not after. Citron's October 2015 report and other short sellers flagged the Philidor structure months before the company restated its 2014 results. The market often treats short reports as noise, but a specific, falsifiable allegation about how a company books revenue deserves investigation. By the time the official restatement arrives, most of the loss has already happened.

Frequently Asked Questions

What was the Valeant scandal in simple terms? The Valeant scandal was the collapse of a drugmaker that grew by buying medicines and sharply raising their prices, then used a secret pharmacy called Philidor to inflate reported sales. When the structure was exposed in late 2015, the stock fell more than 90 percent and regulators and prosecutors brought cases.

Why did the Valeant scandal happen? Valeant's growth depended on price increases and on revenue booked through Philidor, a captive pharmacy it funded but presented as independent. The company also misallocated revenue from a single price increase across more than 100 unrelated products, making concentrated gains look like broad organic growth until short sellers and regulators uncovered it.

How much money was lost in the Valeant scandal? Valeant's stock fell from a record close near $262 in August 2015 to about $11 by March 2017, a decline of more than 90 percent that erased tens of billions in market value. Bill Ackman's Pershing Square exited at a loss estimated between roughly $2.8 billion and $4 billion, and the company later paid a $45 million SEC penalty.

Could a Valeant-style scandal happen again today? Yes. The specific tricks, undisclosed captive channels and misallocated price-increase revenue, can recur wherever disclosure is weak and growth claims go unexamined. The case prompted scrutiny of specialty pharmacy arrangements and drug pricing, but aggressive accounting and roll-up models still appear.

What is the main lesson from the Valeant scandal? Judge revenue by where it actually comes from, not by the growth rate a company advertises. If sales flow through a controlled channel you cannot see, or if growth depends on price increases that regulators are likely to challenge, treat the reported numbers with suspicion.

Sources

1. U.S. Securities and Exchange Commission. Press Release 2020-169: Pharmaceutical Company and Former Executives Charged With Misleading Financial Disclosures. July 31, 2020. https://www.sec.gov/newsroom/press-releases/2020-169
2. U.S. Securities and Exchange Commission. In the Matter of Valeant Pharmaceuticals International, Inc. n/k/a Bausch Health Companies Inc., Securities Act Release No. 33-10809. July 31, 2020. https://www.sec.gov/files/litigation/admin/2020/33-10809.pdf
3. U.S. Department of Justice, U.S. Attorney's Office, Southern District of New York. Former Valeant Executive And Former Philidor CEO Sentenced For Illegal Kickback Scheme. October 30, 2018. https://www.justice.gov/usao-sdny/pr/former-valeant-executive-and-former-philidor-ceo-sentenced-illegal-kickback-scheme
4. U.S. House Committee on Oversight and Government Reform. Cummings and Sanders Ramp Up Investigation of Staggering Drug Price Increases. August 14, 2015. https://oversightdemocrats.house.gov/news/press-releases/cummings-and-sanders-ramp-up-investigation-of-staggering-drug-price-increases
5. Citron Research. Valeant and Philidor RX, The Big Coverup. October 21, 2015. https://citronresearch.com/wp-content/uploads/2015/10/Valeant-Philador-and-RandO-final-a.pdf
6. CNBC. Valeant halted in heavy trading, down 28%, after Citron research report. October 21, 2015. https://www.cnbc.com/2015/10/21/valeant-halted-in-heavy-trading-down-28-after-citron-research-report.html
7. PR Newswire. Valeant Will Become Bausch Health Companies Inc. May 8, 2018. https://www.prnewswire.com/news-releases/valeant-will-become-bausch-health-companies-inc-300644091.html
8. CNBC. Ackman's exit sends Valeant shares to more than 7-year low. March 14, 2017. https://www.cnbc.com/2017/03/14/ackmans-exit-sends-valeant-shares-to-more-than-7-year-low.html

Disclaimer

This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.